Humana Inc. (NYSE:HUM) Stock Holdings Lifted by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 12.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 21,717 shares of the insurance provider’s stock after purchasing an additional 2,395 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Humana were worth $6,879,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Kinsale Capital Group Inc. grew its holdings in shares of Humana by 21.2% during the third quarter. Kinsale Capital Group Inc. now owns 11,777 shares of the insurance provider’s stock valued at $3,730,000 after purchasing an additional 2,062 shares during the last quarter. Natixis Advisors LLC lifted its holdings in shares of Humana by 1.1% in the 3rd quarter. Natixis Advisors LLC now owns 96,375 shares of the insurance provider’s stock worth $30,526,000 after purchasing an additional 1,023 shares during the last quarter. Mizuho Securities USA LLC grew its stake in Humana by 914.2% during the 3rd quarter. Mizuho Securities USA LLC now owns 94,183 shares of the insurance provider’s stock worth $29,832,000 after buying an additional 84,897 shares during the last quarter. Empowered Funds LLC grew its stake in Humana by 164.0% during the 3rd quarter. Empowered Funds LLC now owns 14,914 shares of the insurance provider’s stock worth $4,724,000 after buying an additional 9,264 shares during the last quarter. Finally, Empirical Finance LLC increased its position in Humana by 2.1% in the third quarter. Empirical Finance LLC now owns 4,323 shares of the insurance provider’s stock worth $1,369,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

NYSE HUM opened at $271.35 on Tuesday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18. The business’s fifty day moving average is $279.91 and its two-hundred day moving average is $331.59. The stock has a market capitalization of $32.67 billion, a P/E ratio of 24.03, a P/E/G ratio of 2.17 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, research analysts forecast that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.30%. Humana’s dividend payout ratio is currently 31.36%.

Analysts Set New Price Targets

Several equities analysts have recently commented on HUM shares. JPMorgan Chase & Co. upped their price target on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Royal Bank of Canada decreased their target price on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a report on Tuesday, October 8th. Finally, Piper Sandler downgraded Humana from an “overweight” rating to a “neutral” rating and cut their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.